Cargando…
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594956/ https://www.ncbi.nlm.nih.gov/pubmed/31243293 http://dx.doi.org/10.1038/s41467-019-10844-3 |
_version_ | 1783430321420632064 |
---|---|
author | Godfrey, Laura Crump, Nicholas T. Thorne, Ross Lau, I-Jun Repapi, Emmanouela Dimou, Dimitra Smith, Alastair L. Harman, Joe R. Telenius, Jelena M. Oudelaar, A. Marieke Downes, Damien J. Vyas, Paresh Hughes, Jim R. Milne, Thomas A. |
author_facet | Godfrey, Laura Crump, Nicholas T. Thorne, Ross Lau, I-Jun Repapi, Emmanouela Dimou, Dimitra Smith, Alastair L. Harman, Joe R. Telenius, Jelena M. Oudelaar, A. Marieke Downes, Damien J. Vyas, Paresh Hughes, Jim R. Milne, Thomas A. |
author_sort | Godfrey, Laura |
collection | PubMed |
description | Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells. |
format | Online Article Text |
id | pubmed-6594956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65949562019-06-28 DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation Godfrey, Laura Crump, Nicholas T. Thorne, Ross Lau, I-Jun Repapi, Emmanouela Dimou, Dimitra Smith, Alastair L. Harman, Joe R. Telenius, Jelena M. Oudelaar, A. Marieke Downes, Damien J. Vyas, Paresh Hughes, Jim R. Milne, Thomas A. Nat Commun Article Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells. Nature Publishing Group UK 2019-06-26 /pmc/articles/PMC6594956/ /pubmed/31243293 http://dx.doi.org/10.1038/s41467-019-10844-3 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Godfrey, Laura Crump, Nicholas T. Thorne, Ross Lau, I-Jun Repapi, Emmanouela Dimou, Dimitra Smith, Alastair L. Harman, Joe R. Telenius, Jelena M. Oudelaar, A. Marieke Downes, Damien J. Vyas, Paresh Hughes, Jim R. Milne, Thomas A. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation |
title | DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation |
title_full | DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation |
title_fullStr | DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation |
title_full_unstemmed | DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation |
title_short | DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation |
title_sort | dot1l inhibition reveals a distinct subset of enhancers dependent on h3k79 methylation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594956/ https://www.ncbi.nlm.nih.gov/pubmed/31243293 http://dx.doi.org/10.1038/s41467-019-10844-3 |
work_keys_str_mv | AT godfreylaura dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT crumpnicholast dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT thorneross dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT lauijun dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT repapiemmanouela dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT dimoudimitra dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT smithalastairl dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT harmanjoer dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT teleniusjelenam dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT oudelaaramarieke dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT downesdamienj dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT vyasparesh dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT hughesjimr dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation AT milnethomasa dot1linhibitionrevealsadistinctsubsetofenhancersdependentonh3k79methylation |